

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4056667

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS	
<b>CONVEYING PARTY DATA</b>		
<b>Name</b>		<b>Execution Date</b>
STRATATECH CORPORATION		09/16/2016
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT	
<b>Street Address:</b>	60 WALL STREET	
<b>City:</b>	NEW YORK	
<b>State/Country:</b>	NEW YORK	
<b>Postal Code:</b>	10005	
<b>PROPERTY NUMBERS Total: 27</b>		
<b>Property Type</b>	<b>Number</b>	
Patent Number:	6846675	
Patent Number:	6974697	
Patent Number:	7541188	
Patent Number:	7407805	
Patent Number:	7955790	
Patent Number:	7501238	
Patent Number:	7988959	
Patent Number:	8808685	
Patent Number:	7498167	
Patent Number:	7915042	
Patent Number:	7807148	
Patent Number:	7462448	
Patent Number:	7888496	
Patent Number:	7674291	
Patent Number:	8092531	
Patent Number:	8790636	
Patent Number:	9216202	
Patent Number:	9163076	
Patent Number:	9295543	
Patent Number:	8580314	

PATENT

Property Type	Number
Patent Number:	8685463
Patent Number:	8992997
Application Number:	14335534
Application Number:	12271455
Application Number:	14669095
Application Number:	12784699
Application Number:	14208439

#### CORRESPONDENCE DATA

##### Fax Number:

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

Phone: 6463667120

Email: iprecordations@whitecase.com

Correspondent Name: DANIEL GOLD/WHITE & CASE LLP

Address Line 1: 1155 AVENUE OF THE AMERICAS

Address Line 4: NEW YORK, NEW YORK 10036

ATTORNEY DOCKET NUMBER: 1111779-2453-N997

NAME OF SUBMITTER: DANIEL GOLD

SIGNATURE: /Daniel Gold/

DATE SIGNED: 09/16/2016

##### Total Attachments: 7

source=MNK - IP Supplement - Patents - Stratatech - Executed#page1.tif

source=MNK - IP Supplement - Patents - Stratatech - Executed#page2.tif

source=MNK - IP Supplement - Patents - Stratatech - Executed#page3.tif

source=MNK - IP Supplement - Patents - Stratatech - Executed#page4.tif

source=MNK - IP Supplement - Patents - Stratatech - Executed#page5.tif

source=MNK - IP Supplement - Patents - Stratatech - Executed#page6.tif

source=MNK - IP Supplement - Patents - Stratatech - Executed#page7.tif

## **Notice of Grant of Security Interest in Intellectual Property**

NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS, dated as of September 16, 2016 (this “**Agreement**”), made by Stratatech Corporation, a Delaware corporation (the “**Pledgor**”), in favor of DEUTSCHE BANK AG NEW YORK BRANCH, as Collateral Agent (as defined below).

Reference is made to the U.S. Collateral Agreement dated as of March 19, 2014 (as amended, restated, supplemented or otherwise modified from time to time, the “**U.S. Collateral Agreement**”), among Mallinckrodt International Finance S.A., a public limited liability company (*société anonyme*) incorporated under the laws of the Grand Duchy of Luxembourg, having its registered office at 42-44, Avenue de la Gare, L-1610 Luxembourg, and registered with the Luxembourg Trade and Companies Register (*R.C.S Luxembourg*) under number B 172.865 (the “**Lux Borrower**”), MALLINCKRODT CB LLC (the “**Co-Borrower**”, and together with the Lux Borrower, the “**Borrowers**”), Mallinckrodt Finance GmbH (the “**Swiss Finco**”), each other Subsidiary Loan Party listed on the signature pages hereof and each other Subsidiary Loan Party that becomes a party hereto after the date hereof (together with the Lux Borrower, the Co-Borrower and the Swiss Finco, collectively, the “**Pledgors**”) and DEUTSCHE BANK AG NEW YORK BRANCH, as collateral agent (together with its successors and assigns in such capacity, the “**Collateral Agent**”) for the Secured Parties (as defined therein). The parties hereto agree as follows:

SECTION 1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the U.S. Collateral Agreement. The rules of construction specified in Section 1.01(b) of the U.S. Collateral Agreement also apply to this Agreement.

SECTION 2. **Grant of Security Interest.** As security for the payment and performance, as applicable, in full of its Secured Obligations, the Pledgor pursuant to the U.S. Collateral Agreement did, and hereby does, assign and pledge to the Collateral Agent, its successors and permitted assigns, for the benefit of the Secured Parties, a continuing security interest in all of such Pledgor’s right, title and interest in, to and under any and all of the following assets now owned or at any time hereafter acquired by such Pledgor or in which such Pledgor now has or at any time in the future may acquire any right, title or interest (collectively, but excluding any Excluded Property, the “**IP Collateral**”):

all Patents of the United States of America, including those listed on Schedule I;

SECTION 3. **U.S. Collateral Agreement.** The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the U.S. Collateral Agreement. Each Pledgor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the U.S. Collateral Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the U.S. Collateral Agreement, the terms of the U.S. Collateral Agreement shall govern.


SECTION 4. *Counterparts*. This Agreement may be executed in two or more counterparts, each of which shall constitute an original but all of which when taken together shall constitute but one contract. Delivery of an executed counterpart to this Agreement by facsimile or other electronic transmission shall be as effective as delivery of a manually signed original.

SECTION 5. *Governing Law*. **THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW YORK.**

[Signature Pages Follow]

IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and year first above written.


STRATATECH CORPORATION

By:   
Name: John Einwalter  
Title: Vice President & Treasurer

*[Signature Page to Notice of Grant of Security Interest in Patents]*

**PATENT**  
**REEL: 040059 FRAME: 0226**

DEUTSCHE BANK AG NEW YORK  
BRANCH,  
as Collateral Agent,

By:   
Name: Dusan Lazarov  
Title: Director

By:   
Name: Anca Trifan  
Title: Managing Director

*[Signature Page to Notice of Grant of Security Interest in Patents]*

Schedule I  
to Notice of Grant of Security Interest in Patents

Patents Owned by Stratatech Corporation

*U.S. Patent Registrations*

<b>Patent</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Owner</b>
SKIN SUBSTITUTES AND USES THEREOF	6,846,675	25-Jan-2005	STRATATECH CORPORATION
SKIN SUBSTITUTES WITH IMPROVED BARRIER FUNCTION	6,974,697	13-Dec-2005	STRATATECH CORPORATION
SKIN SUBSTITUTES AND USES THEREOF	7,541,188	02-Jun-2009	STRATATECH CORPORATION
SKIN SUBSTITUTES WITH IMPROVED BARRIER FUNCTION	7,407,805	05-Aug-2008	STRATATECH CORPORATION
SKIN SUBSTITUTES WITH IMPROVED BARRIER FUNCTION	7,955,790	07-Jun-2011	STRATATECH CORPORATION
SKIN SUBSTITUTES FOR IRRITANCY TESTING	7,501,238	10-Mar-2009	STRATATECH CORPORATION
METHOD OF TREATMENT USING ORGANOTYPICALLY CULTURED SKIN TISSUE COMPRISING NIKS CELLS THAT EXPRESS EXOGENOUS HIF-1A	7,988,959	02-Aug-2011	STRATATECH CORPORATION
METHOD OF TREATMENT USING ORGANOTYPICALLY CULTURED SKIN TISSUE COMPRISING NIKS CELLS THAT EXPRESS EXOGENOUS HIF-1A	8,808,685	19-Aug-2014	STRATATECH CORPORATION
KERATINOCYTES EXPRESSING EXOGENOUS ANGIOGENIC GROWTH FACTORS	7,498,167	03-Mar-2009	STRATATECH CORPORATION
KERATINOCYTES EXPRESSING EXOGENOUS ANGIOGENIC GROWTH FACTORS	7,915,042	29-Mar-2011	STRATATECH CORPORATION
ORGANOTYPICALLY CULTURED SKIN TISSUE COMPRISING NIKS CELLS THAT EXPRESS EXOGENOUS HIF-1A	7,807,148	05-Oct-2010	STRATATECH CORPORATION
SPECIES SPECIFIC DNA DETECTION	7,462,448	09-Dec-2008	STRATATECH CORPORATION
KIT FOR SPECIES SPECIFIC DNA DETECTION	7,888,496	15-Feb-2011	STRATATECH CORPORATION

<b>Patent</b>	<b>Patent No.</b>	<b>Issue Date</b>	<b>Owner</b>
HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES	7,674,291	09-Mar-2010	STRATATECH CORPORATION
HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES	8,092,531	10-Jan-2012	STRATATECH CORPORATION
HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES	8,790,636	29-Jul-2014	STRATATECH CORPORATION
METHODS AND COMPOSITIONS FOR SELECTING CELLS WITH INCREASED POTENCY	9,216,202	22-Dec-2015	STRATATECH CORPORATION
HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES	9,163,076	20-Oct-2015	STRATATECH CORPORATION
SKIN SUBSTITUTES WITH IMPROVED PURITY	9,295,543	29-Mar-2016	STRATATECH CORPORATION
DRIED AND IRRADIATED SKIN EQUIVALENTS FOR READY USE	8,580,314	12-Nov-2013	STRATATECH CORPORATION
DRIED AND IRRADIATED SKIN EQUIVALENTS FOR READY USE	8,685,463	01-Apr-2014	STRATATECH CORPORATION
DRIED AND IRRADIATED SKIN EQUIVALENTS FOR READY USE	8,992,997	31-Mar-2015	STRATATECH CORPORATION

*U.S. Patent Applications*

<b>Patent</b>	<b>Application No.</b>	<b>Application Date</b>	<b>Owner</b>
HUMAN SKIN EQUIVALENTS EXPRESSING EXOGENOUS POLYPEPTIDES	14/335,534	18-Jul-2014	STRATATECH CORPORATION
COLD STORAGE OF ORGANOTYPICALLY CULTURED SKIN EQUIVALENTS FOR CLINICAL APPLICATIONS	12/271,455	14-Nov-2008	STRATATECH CORPORATION
DRIED AND IRRADIATED SKIN EQUIVALENTS FOR READY USE	14/669,095	26-Mar-2015	STRATATECH CORPORATION



USE OF HUMAN SKIN SUBSTITUTES EXPRESSING IL-12	12/784,699	21-May-2010	STRATATECH CORPORATION
CRYOPRESERVATION OF VIABLE HUMAN SKIN SUBSTITUTES	14/208,439	13-Mar-2014	STRATATECH CORPORATION